Lilly Q3 revenue up 39% on Mounjaro and Zepbound; annual outlook raised
Eli Lilly's third-quarter revenue rose 39% to $24.4 billion, and full-year guidance was lifted to $91–92 billion. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Eli Lilly (ticker LLY) reported third-quarter revenue up 39% to $24.4 billion. TradingView says the growth was led by Mounjaro and Zepbound.
The company also raised its full-year revenue guidance to $91–92 billion. EPS growth was held back by $4.57 per share in acquired IPR&D charges.
why it matters
A higher annual forecast on strong sales matters for the whole pharmaceutical sector and for the largest companies in the industry. The IPR&D charges distort the profit comparison, so investors will focus mainly on revenue and guidance.
market impact
LLY shares: strong revenue and a raised forecast support the stock
- Eli Lilly (LLY) shares pressure up — a raised revenue forecast and fast sales growth support demand for the stock
tags
instruments
sources
- LLY: Mounjaro and Zepbound drove 39% Q3 growth; FY revenue outlook rose to $91–92B — TradingView, 29 October 2026 at 11:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗